Prescription medication · Anti-IL-23 Monoclonal Antibody

risankizumab

Also sold as Skyrizi. Skyrizi is used to treat moderate to severe plaque psoriasis in adults.

Data updated 2026-05-15

$20211.78
Brand price (NADAC)

risankizumab (Skyrizi) is a prescription Anti-IL-23 Monoclonal Antibody. Skyrizi is used to treat moderate to severe plaque psoriasis in adults.

Skyrizi is a medicine that can help reduce inflammation in your body. It is used to treat conditions like psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

Verify with FDA → · CMS NADAC pricing →

Drug Pricing (NADAC)

Brand Price

$20211.78/unit

Generic Available

No

Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →

View Alternatives → Compare with Another Drug →

What it does

Skyrizi is used to treat moderate to severe plaque psoriasis in adults.

Common side effects

Upper respiratory infections (like a cold), Headache, Fatigue

Key warnings

Serious allergic reactions, including anaphylaxis, can happen.

The sections below are summarized in plain English from risankizumab's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.

How It Works

Skyrizi is a type of antibody that blocks a protein called interleukin-23 (IL-23). IL-23 causes inflammation in the body. By blocking IL-23, Skyrizi helps to reduce inflammation and the symptoms of certain diseases.

Serious Warnings

Serious allergic reactions, including anaphylaxis, can happen. If you have an infection, tell your doctor. Skyrizi may increase your risk of getting an infection or make an existing infection worse. Your doctor will check you for tuberculosis (TB) before you start Skyrizi. For inflammatory bowel disease, Skyrizi can cause liver problems. Your doctor will check your liver before and during treatment.

Common Questions

What should I tell my doctor before taking Skyrizi?
Tell your doctor about all your medical conditions, including any infections, liver problems, or history of TB.
Can I get vaccines while taking Skyrizi?
Avoid live vaccines while taking Skyrizi.
What are the symptoms of an allergic reaction?
Symptoms can include rash, hives, swelling of the face, lips, or tongue, and trouble breathing.
How often will I need to get injections?
For psoriasis and psoriatic arthritis, injections are given at Week 0, Week 4, and then every 12 weeks.
Will Skyrizi cure my condition?
Skyrizi helps manage the symptoms of your condition. It is not a cure.
Can I take Skyrizi with other medications?
Talk to your doctor about all the medicines you take, including prescription and over-the-counter drugs, vitamins, and herbal supplements.
What if I have side effects?
Tell your doctor if you have any side effects that bother you or do not go away.
How long does Skyrizi stay in my system?
It is not exactly known how long Skyrizi stays in your system after your last dose.
Can Skyrizi affect my immune system?
Yes, Skyrizi can weaken your immune system, making you more likely to get infections.
What tests will I need before starting Skyrizi?
Your doctor will check your liver and test you for TB before you start Skyrizi.
What are the common side effects of risankizumab?
The registry lists Upper respiratory infections (like a cold), Headache, Fatigue, Injection site reactions (redness, pain, or swelling), Tinea infections (like ringworm) among the most-reported FAERS reaction terms for risankizumab. These counts are not an individual symptom assessment.
What drug class is risankizumab?
risankizumab belongs to the Anti-IL-23 Monoclonal Antibody drug class. It requires a prescription (Rx). Skyrizi is used to treat moderate to severe plaque psoriasis in adults.
What pregnancy or breastfeeding source fields are listed for risankizumab?
The FDA label for risankizumab contains product-specific pregnancy or breastfeeding language. PlainMeds does not apply that source text to an individual.

Related Medications in Anti-IL-23 Monoclonal Antibody

Other drugs grouped near risankizumab - same-class peers and common alternatives.

adapalene

Differin

Compare with risankizumab →

apremilast

Otezla

Apremilast (Otezla/Otezla XR) is a medicine that can help adults and children manage psoriatic arthritis and psoriasis.

Compare with risankizumab →

azelaic acid

Finacea, Azelex

Azelaic acid gel is a topical medicine that helps treat rosacea.

Compare with risankizumab →

benzoyl peroxide

Benzac, PanOxyl

Benzoyl peroxide is a topical medicine that fights germs on your skin.

Compare with risankizumab →

betamethasone

Diprosone, Luxiq

Betamethasone dipropionate cream is a strong steroid medicine used on the skin.

Compare with risankizumab →

Compare risankizumab vs adapalene side-by-side →

Medication Guides

Understanding Drug Interactions

How CYP450 enzymes, inhibitors, and inducers affect your medications

Generic vs Brand Name Drugs

FDA requirements, cost savings, and when the difference matters

Narrow Therapeutic Index Drugs

FDA bioequivalence and label-record context for narrow therapeutic index medicines

Common Drug Interactions

Dangerous medication combinations and how to protect yourself

Save on risankizumab

Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.

Check Prices on GoodRx →

Disclosure: This link may earn us a commission at no extra cost to you. See our terms.

What the FDA Data Shows for risankizumab

The FDA label for risankizumab (sold under brand names such as Skyrizi) classifies it as a prescription-only medication in the Anti-IL-23 Monoclonal Antibody class. Skyrizi is used to treat moderate to severe plaque psoriasis in adults. Official labeling lists 5 commonly reported side effects, including Upper respiratory infections (like a cold), Headache, Fatigue.

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. Voluntary reports accumulate over the lifetime of a drug and reflect wide-ranging clinical use. Interaction data is drawn directly from FDA-approved prescribing information. NADAC pricing from CMS.

Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.

Last updated: September 3, 2025

PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.

Read our methodology - how this data is sourced, computed, and verified.

Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.

All federal data sources used on this page